Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;1(3):115.
Epub 2018 Mar 7.

Liquid Biopsy in the OMICS Era of Tumor Medicine

Yi Jiang  1 , Denong Wang  1
Affiliations

Liquid Biopsy in the OMICS Era of Tumor Medicine

Yi Jiang et al. Open Access J Biomed Eng Appl. 2018.

Abstract

Liquid biopsy uses noninvasive blood test to assess tumor heterogeneity and evolution in real time. It looks for tumor components in the blood circulation, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), to provide tumor-specific information. By detecting multiplex tumor biomarkers, including nucleic acids, proteins, carbohydrates, and other tumor-derived substances, liquid biopsy helps with early tumor diagnosis, tumor evolution monitoring, and prognosis prediction. With the development of high-throughput OMICS tools like carbohydrate microarray and high-speed fiber-optic array scanning technology (FAST scan), it is now practical to identify glycan markers of CTCs and cancer stem cells (CSCs), especially those that are cell-surface exposed and readily accessible for immune recognition and targeting. Potential of this class of biomarkers in tumor subtyping and targeted immunotherapy is yet to be explored.

Keywords: Blood group precursor; Cancer stem cells; Carbohydrate microarray; Circulating tumor DNA; Circulating tumor cells; Glycan markers; Glycomics; Liquid biopsy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224–224. - PMC - PubMed
    1. Dhar M, Wong J, Che J, Matsumoto M, Grogan T, et al. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep. 2018;8(1):2592. - PMC - PubMed
    1. Haber DA, VE Velculescu. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650–661. - PMC - PubMed
    1. Hench IB, Hench J, Tolnay M. Liquid biopsy in clinical management of breast, lung, and colorectal cancer. Front Med (Lausanne) 2018;5:9. - PMC - PubMed
    1. Chiotaki R, Polioudaki H, Theodoropoulos PA. Cancer stem cells in solid and liquid tissues of breast cancer patients: characterization and therapeutic perspectives. Curr Cancer Drug Targets. 2015;15(3):256–269. - PubMed

LinkOut - more resources

-